Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Esophageal Cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2019, there were 578,600 incident cases of esophageal cancer worldwide, and expects that number to increase to 618,900 incident cases by 2028.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, Bristol Myers Squibb’s Opdivo, and Jiangsu Hengrui’s camrelizumab are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II, with two drugs in the NDA/BLA phase.
- Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, with the remainder being oral and intratumoral formulations.
- High-impact upcoming events for drugs in the esophageal cancer space comprise topline Phase II trial results for ADPA2M4CD8, topline Phase III trial results for Imfinzi and tiragolumab, and expected PDUFA dates for Yervoy, Opdivo, and tislelizumab.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 42.1%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for esophageal cancer, with 76 trials.
- Roche leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, closely followed by Bristol Myers Squibb.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Sintilimab for Esophageal Cancer (September 17, 2021)
25 Toripalimab for Esophageal Cancer (September 16, 2021)
27 Multiple Drugs for Esophageal Cancer (July 28, 2021)
28 Sintilimab for Esophageal Cancer (June 22, 2021)
29 Tislelizumab for Esophageal Cancer (June 4, 2021)
31 Opdivo for Esophageal Cancer (June 3, 2021)
33 Camrelizumab for Esophageal Cancer (May 28, 2021)
34 Tislelizumab for Esophageal Cancer (January 27, 2021)
36 Keytruda for Esophageal Cancer (September 21, 2020)
38 Opdivo for Esophageal Cancer (September 21, 2020)
40 Opdivo for Esophageal Cancer (September 21, 2020)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 CHMP Recommends Yervoy and Opdivo Combination For Use In Esophageal Cancer
44 Novartis’s Tislelizumab Takes First Step On US Approval Path
44 Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products
44 Keytruda May Stay Competitive In Gastric Cancer Despite Losing Third-Line Claim
45 Keytruda’s Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
45 Opdivo First-Line Gastric Cancer Claim Used RTOR
45 Merck Builds Keytruda Esophageal Carcinoma Label Under RTOR
47 PROBABILITY OF SUCCESS
48 LICENSING AND ASSET ACQUISITION DEALS
48 China CSPC Subsidiary Out-Licenses Oncology Candidate To Flame Biosciences
49 REVENUE OPPORTUNITY
50 CLINICAL TRIAL LANDSCAPE
51 Sponsors by status
52 Sponsors by phase
53 Recent events
56 BIBLIOGRAPHY
57 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2019–28
14 Figure 2: Incident cases of esophageal cancer, by gender, 2019
17 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
17 Figure 4: Pipeline drugs for esophageal cancer, by company
18 Figure 5: Pipeline drugs for esophageal cancer, by drug type
18 Figure 6: Pipeline drugs for esophageal cancer, by classification
25 Figure 7: Sintilimab for Esophageal Cancer (September 17, 2021): Phase III – ORIENT-15 (Global)
29 Figure 8: Sintilimab for Esophageal Cancer (June 22, 2021): Phase III – ORIENT-15 (Global)
31 Figure 9: Tislelizumab for Esophageal Cancer (June 4, 2021): Phase III – RATIONALE 302
33 Figure 10: Opdivo for Esophageal Cancer (June 3, 2021): Phase III – CheckMate 648
36 Figure 11: Tislelizumab for Esophageal Cancer (January 27, 2021): Phase III – RATIONALE 302
38 Figure 12: Keytruda for Esophageal Cancer (September 21, 2020): Phase III – KEYNOTE-590
40 Figure 13: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-649
42 Figure 14: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-577
43 Figure 15: Key upcoming events in esophageal cancer
47 Figure 16: Probability of success in the solid tumors pipeline
50 Figure 17: Clinical trials in esophageal cancer
50 Figure 18: Top 10 drugs for clinical trials in esophageal cancer
51 Figure 19: Top 10 companies for clinical trials in esophageal cancer
51 Figure 20: Trial locations in esophageal cancer
52 Figure 21: Esophageal cancer trials status
53 Figure 22: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2019–28
16 Table 2: Marketed drugs for esophageal cancer
19 Table 3: Pipeline drugs for esophageal cancer in the US
24 Table 4: Sintilimab for Esophageal Cancer (September 17, 2021)
26 Table 5: Toripalimab for Esophageal Cancer (September 16, 2021)
27 Table 6: Multiple Drugs for Esophageal Cancer (July 28, 2021)
28 Table 7: Sintilimab for Esophageal Cancer (June 22, 2021)
30 Table 8: Tislelizumab for Esophageal Cancer (June 4, 2021)
32 Table 9: Opdivo for Esophageal Cancer (June 3, 2021)
34 Table 10: Camrelizumab for Esophageal Cancer (May 28, 2021)
35 Table 11: Tislelizumab for Esophageal Cancer (January 27, 2021)
37 Table 12: Keytruda for Esophageal Cancer (September 21, 2020)
39 Table 13: Opdivo for Esophageal Cancer (September 21, 2020)
41 Table 14: Opdivo for Esophageal Cancer (September 21, 2020)
49 Table 15: Historical global sales, by drug ($m), 2016–20
49 Table 16: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Zika virus 
Sign up to the